These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22283887)

  • 1. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.
    Gammino VM; Taylor AB; Rich ML; Bayona J; Becerra MC; Bonilla C; Gelmanova I; Hollo V; Jaramillo E; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riektsina V; Tupasi TE; Wells CD; Zignol M; Cegielski PJ
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1315-22. PubMed ID: 22283887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.
    Kurbatova EV; Gammino VM; Bayona J; Becerra M; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1553-5, i. PubMed ID: 22008772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of the INNO-LiPA Rif. TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia.
    Skenders GK; Holtz TH; Riekstina V; Leimane V
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1546-52, i. PubMed ID: 22008771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.
    Kurbatova EV; Gammino VM; Bayona J; Becerra MC; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1335-43. PubMed ID: 23107633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
    Holtz TH; Sternberg M; Kammerer S; Laserson KF; Riekstina V; Zarovska E; Skripconoka V; Wells CD; Leimane V
    Ann Intern Med; 2006 May; 144(9):650-9. PubMed ID: 16670134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.
    Mitnick C; Bayona J; Palacios E; Shin S; Furin J; Alcántara F; Sánchez E; Sarria M; Becerra M; Fawzi MC; Kapiga S; Neuberg D; Maguire JH; Kim JY; Farmer P
    N Engl J Med; 2003 Jan; 348(2):119-28. PubMed ID: 12519922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug-resistant tuberculosis among previously treated patients in the Philippines.
    Gler MT; Macalintal LE; Raymond L; Guilatco R; Quelapio MI; Tupasi TE
    Int J Tuberc Lung Dis; 2011 May; 15(5):652-6. PubMed ID: 21756517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it.
    Parikh R; Nataraj G; Kanade S; Khatri V; Mehta P
    J Assoc Physicians India; 2012 Aug; 60():22-6. PubMed ID: 23405517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence after successful treatment among patients with multidrug-resistant tuberculosis.
    Lee J; Lim HJ; Cho YJ; Park YS; Lee SM; Yang SC; Yoo CG; Kim YW; Han SK; Yim JJ
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1331-3. PubMed ID: 22283890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.
    Chavez Pachas AM; Blank R; Smith Fawzi MC; Bayona J; Becerra MC; Mitnick CD
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):52-8. PubMed ID: 14974746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
    Putri FA; Burhan E; Nawas A; Soepandi PZ; Sutoyo DK; Agustin H; Isbaniah F; Dowdy DW
    Int J Tuberc Lung Dis; 2014 May; 18(5):564-70. PubMed ID: 24903794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
    Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of previous tuberculosis treatment history on acid-fast bacilli smear and culture conversion.
    Lee J; Lee BJ; Yoon HI; Lee CT; Lee JH
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1344-8. PubMed ID: 23107634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan.
    Qazi F; Khan U; Khowaja S; Javaid M; Ahmed A; Salahuddin N; Hussain H; Becerra MC; Golub JE; Khan AJ
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1556-9, i. PubMed ID: 22008773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
    Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis.
    Chan ED; Laurel V; Strand MJ; Chan JF; Huynh ML; Goble M; Iseman MD
    Am J Respir Crit Care Med; 2004 May; 169(10):1103-9. PubMed ID: 14742301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
    Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
    Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China.
    Qi W; Harries AD; Hinderaker SG
    Int J Tuberc Lung Dis; 2011 Jan; 15(1):137-9. PubMed ID: 21276311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.